Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022
04/06/2022 - 07:59 AM
AUSTIN, Texas April 6, 2022
Conference: 21st Annual Needham Virtual Healthcare Conference, April 11-14, 2022 9:30 a.m. EDT https://wsw.com/webcast/needham117/agle/2213747
To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021 , Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com
https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-the-needham-virtual-healthcare-conferences-in-april-2022-301518753.html
SOURCE Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics Inc
AGLE Rankings
#4882 Ranked by Stock Gains
AGLE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About AGLE
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
